Mallinckrodt plc

Track this case

Case Number:

1:20-bk-12522

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

January 25, 2022
Mallinckrodt, Fresenius Reach $14M Deal On Supply Claims

Drugmaker Mallinckrodt PLC is asking a Delaware bankruptcy judge to approve a $13.9 million settlement with a subsidiary of German pharmaceutical company Fresenius Kabi to end a dispute over supply payments Mallinckrodt cut off when it entered Chapter 11.
January 06, 2022
Mallinckrodt Says Ch. 11 Plan Fair For Acthar Claimants

Mallinckrodt PLC Thursday made its final arguments for its Chapter 11 plan to a Delaware bankruptcy judge, with the drugmaker defending the plan against assertions that it's unfair to holders of claims connected to its Acthar gel and contains improper liability releases.
January 04, 2022
Acthar Claimants Call Mallinckrodt's Ch. 11 Plan Unfair

Holders of claims connected to Mallinckrodt PLC's Acthar gel made their final arguments to a Delaware bankruptcy judge on Tuesday that they will receive an unfairly small cash share from the unsecured creditor settlement in the drugmaker's proposed Chapter 11 plan.
December 17, 2021
Mallinckrodt Balks At Bid To Withdraw Acthar Antitrust Claims

Mallinckrodt objected to a request by Acthar antitrust claimants to withdraw their Chapter 11 claims, telling a Delaware bankruptcy judge Friday that it needs a ruling on the claims to secure a post-bankruptcy distribution deal.
December 13, 2021
Mallinckrodt Says $1.75B Ch. 11 Opioid Deal Is Reasonable

Witnesses for supporters of Mallinckrodt's proposed Chapter 11 plan Monday told a Delaware bankruptcy judge that the plan's proposed $1.75 billion opioid claims deal is reasonable and the distribution of its unsecured creditors' settlement is fair.
December 10, 2021
Mallinckrodt Calls Opioid, Acthar Deals Vital To Ch. 11 Plan

A restructuring adviser for Mallinckrodt told a Delaware bankruptcy judge Friday that the drugmaker's proposed Chapter 11 plan would be impossible without the company's settlements of opioid injury and federal Acthar reimbursement claims.
December 07, 2021
Mallinckrodt Exec Says Ch. 11 Plan A Fair Deal For Creditors

Mallinckrodt's top restructuring executive defended the fairness of the drugmaker's proposed Chapter 11 plan on Tuesday, as he faced questions about whether it would shortchange holders of antitrust claims over the sales of its Acthar gel.
December 06, 2021
Mallinckrodt Escapes $320M Acthar Antitrust Claim In Ch. 11

A Delaware bankruptcy judge Monday rejected a bid by insurers for a $320 million priority antitrust claim in Mallinckrodt's Chapter 11 case, saying they had failed to show it was the drugmaker and not federal regulators that kept competition to its Acthar gel off the market.
November 29, 2021
Mallinckrodt Gets Ch. 11 Stay Of Acthar Suits Extended

A Delaware bankruptcy judge agreed Monday with drugmaker Mallinckrodt PLC that more than a dozen lawsuits against the debtor relating to its marketing of Acthar gel products should be paused for an additional 90 days so that plan confirmation proceedings aren't derailed in the coming weeks.
November 22, 2021
Judge Rejects Probe Of Asbestos Votes In Mallinckrodt Ch. 11

A Delaware bankruptcy judge on Monday denied a call for a probe into votes cast for the Mallinckrodt Chapter 11 plan by parties with asbestos claims against the drugmaker, saying the company had met the legal standard for checking the validity of the ballots.